Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P830055/S377

ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Revision Rotating Platform (RP) Total Knee System, and M.B.T. Re

Depuy, Inc. · Decision date Oct 8, 2026

MEDTECHLEDGER EXPLANATIONP830055/S377

What did the FDA decide?

FDA's record for P830055/S377, dated 2026-10-08, carries the decision code OK30 and is filed as a 30-Day Notice under reason 'Process Change - Manufacturer/Sterilizer/Packager/Supplier.' The reported statement describes 'an additional hot isostatic pressure parameter cycle at supplier Lake City Heat Treating for some metallic components approved under LCS Total Knee System.' The listed title covers the ATTUNE Rotating Platform Total Knee System, the ATTUNE Revision Rotating Platform Total Knee System, and an M.B.T. Re entry whose full text is truncated in the supplied fields.

The identifier places S377 as a supplement to PMA P830055, so the filing concerns a manufacturing-process notice within that approval rather than an original PMA decision. The notice's stated purpose is a supplier-side change; it does not itself demonstrate safety or clinical effectiveness. The record does not specify which metallic components are affected, the parameter values or cycle count added, prior versus new conditions, or how the Lake City Heat Treating change maps to each listed knee system, and the product title's third entry remains incomplete.

FDA approval order statement

an additional hot isostatic pressure parameter cycle at supplier Lake City Heat Treating for some metallic components approved under LCS Total Knee System
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Oct 8, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P830055/S377
Regulatory pathway
PMA supplement
Applicant
Depuy, Inc.
Product code
NJL
Decision code
OK30
Decision date
Oct 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, knee, patellofemorotibial, semi-constrained, metal/polymer, mobile bearing.

Applicant
Depuy, Inc.
Product code
NJL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P830055/S374 · Related supplement

    LCS(R) TOTAL KNEE SYSTEM, specifically ATTUNE Cruciate Retaining (CR), Posterior Stabilized (PS) and Revision Femoral C

  2. P830055/S372 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, ATTUNE Cementless Rotating Platform (RP) Knee System, ATTUNE Revision R

  3. P830055/S376 · Related supplement

    Attune Rotating Platform (RP) Total Knee System and the DePuy P.F.C. Sigma Rotating Platform (RP) Total Knee System an

  4. P830055/S377 received

    Application receipt date recorded by FDA.

  5. P830055/S351 · Related supplement

    Attune Revision Knee System

  6. P830055/S377 · FDA decision

    30-Day Notice

  7. P830055/S379 · Related supplement

    ATTUNE Revision Knee System

  8. P830055/S381 · Related supplement

    ATTUNE Rotating Platform (RP) Total Knee System, and ATTUNE Revision Rotating Platform (RP) Knee System

Timeline entries are records held by MedtechLedger for P830055. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P830055

Explore the linked device profile

Other records with product code NJL

Product / regulatory recordCompanyPathwayDecision dateSource
Zimmer, Inc.PMA supplementOct 16, 2026FDA
Zimmer, Inc.PMA supplementSep 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Depuy, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
P.O. Box 988, 700 Orthopaedic Dr., Warsaw, IN, 46581

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records